Last updated: February 13, 2026
Overview
NDC 00002-3235 corresponds to Doxorubicin HCl Liposomal Injection, marketed as Doxil by Janssen Pharmaceuticals. It is a targeted chemotherapeutic agent approved for ovarian cancer, multiple myeloma, and AIDS-related Kaposi’s sarcoma. The drug's patent expired in 2013, leading to increased generic availability and market competition.
Market Size and Trends
- Global Oncology Market: The therapeutic area is expected to reach $282 billion by 2026, growing at a Compound Annual Growth Rate (CAGR) of approximately 7.8% (source: Global Market Insights).
- Liposomal Doxorubicin Market: Estimated to grow from $1.1 billion in 2021 to around $2.4 billion by 2028, with a CAGR of approximately 11% (source: Fortune Business Insights).
- Market Share: Doxil’s initial dominance declined post-patent expiration. Now, generic versions and biosimilars capture a significant portion, impacting branded prices.
Pricing Dynamics
- Brand Price: Doxil’s wholesale acquisition cost (WAC) historically ranged from $2,500 to $3,500 per infusion (per 50 mg vial). Biosimilar and generic prices now range from $1,500 to $2,200.
- Generic Entry: Since 2014, multiple manufacturers have entered the market, significantly reducing prices. The typical generic Doxorubicin Liposomal has seen a price reduction of approximately 40-60% within 3 years of market entry.
- Market Penetration: Generic versions capture nearly 85% of prescriptions, leading to downward pressure on prices.
Price Projection Models
- Short-term (1-2 years): Prices likely to stabilize at $1,200 - $1,800 per vial, given current market saturation and manufacturing costs.
- Mid-term (3-5 years): Prices could further decline to $1,000 - $1,500 per vial if manufacturing efficiencies improve and more biosimilars enter the market.
- Long-term (5+ years): Potential for stabilization at $800 - $1,200 per vial, especially if new patents or formulations extend exclusivity or if biosimilar competition intensifies.
Influencing Factors
- Patent and Exclusivity Status: No active patents for Doxil; exclusivity expired in 2013, increasing generic entry.
- Reimbursement Policies: Coverage influenced by payer negotiations; increased competitive pressure may lower copayments.
- Manufacturing Costs: Liposomal formulations are complex, which limits drastic price collapses; cost reductions depend on scale and process innovations.
- Regulatory Environment: Approval of biosimilars by the FDA can accelerate price reductions.
Competitive Landscape
- Major Manufacturers: Teva, Sun Pharma, Sandoz, among others, produce generic liposomal doxorubicin.
- Biosimilars in Development: Several biosimilars are in early-stage development, with some expected FDA submission within 2-3 years.
Conclusion
The market for NDC 00002-3235 has transitioned from high-priced branded therapy to a highly competitive landscape dominated by generics. Prices have declined significantly since patent expiry, with further decreases expected due to ongoing biosimilar development and market saturation.
Key Takeaways
- The original branded product, Doxil, peaked at approximately $2,500–$3,500 per vial.
- Generic and biosimilar competition has reduced prices by up to 60% since patent expiry.
- Current price forecasts suggest stabilization between $800 and $1,500 per vial within five years.
- Market growth is driven by the expanding oncology sector and increasing adoption of liposomal formulations.
- Future price changes will depend on biosimilar approvals, regulatory policies, and manufacturing efficiencies.
FAQs
-
What is the primary driver for price declines in liposomal doxorubicin?
The expiration of patents and entry of multiple generics have increased competition, resulting in significant price reductions.
-
Are biosimilars expected to impact prices further?
Yes. If biosimilars gain FDA approval and market adoption increases, prices are likely to decrease further.
-
How do reimbursement policies influence pricing?
Reimbursement negotiations and formulary placements can either support higher prices for branded drugs or push for lower prices through generic substitution.
-
What is the impact of manufacturing costs on the price?
Liposomal formulations are complex and costly to produce, limiting rapid price declines unless economies of scale or process innovations occur.
-
When might prices stabilize at current levels?
Prices are expected to stabilize in the $800–$1,200 range over the next 3-5 years as market dynamics settle.
Citations
[1] Global Market Insights, "Oncology Market Outlook," 2022.
[2] Fortune Business Insights, "Liposomal Drug Market Size," 2022.
[3] U.S. FDA, "Drug Approvals and Market Exclusivity," 2023.
[4] IQVIA, "Sterile Injectable Market Data," 2022.
